# Effective Dose and Safety of Esketamine During Ultrasound-guided Hepatic Tumor Thermal Ablation

> **NCT07034950** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **The First Affiliated Hospital of Xiamen University** · enrollment: 79 (estimated)

## Conditions studied

- Hepatic Neoplasm
- Hepatic Cancer

## Interventions

- **DRUG:** Intravenous esketamine using Dixon's up-and-down sequential method
- **DRUG:** Intravenous the dose of esketamine ED95
- **DRUG:** Intravenous fentanyl 1 μg∙kg-1

## Key facts

- **NCT ID:** NCT07034950
- **Lead sponsor:** The First Affiliated Hospital of Xiamen University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-06-29
- **Primary completion:** 2028-06-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 79 (ESTIMATED)
- **Last updated:** 2025-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07034950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07034950, "Effective Dose and Safety of Esketamine During Ultrasound-guided Hepatic Tumor Thermal Ablation". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07034950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*